Work

Figure S4 from Targeting Semaphorin 7a Signaling in Preclinical Models of Endocrine Therapy–Resistant Breast Cancer

Year: 2026

Type: other

Abstract: Figure S4 shows IC50 curves and cell viability for fulvestrant and/or alpelisib in vitro, and in vivo results after fulvestrant and/or PI3K inhibitor treatment in ER+ mouse models.

DOI: 10.1158/1535-7163.33414249

Authors: Rachel N. Steinmetz, Veronica Wessells, Heather Fairchild, Virgina F. Borges, Traci R. Lyons

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7204995539

Cites:

Cited by:

Related to: